{'fraction_non_alphanumeric': 0.03977669225401256, 'fraction_numerical': 0.01465457083042568, 'mean_word_length': 5.102127659574468, 'pattern_counts': {'":': 0, '<': 1, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Identification and biochemical characterization of a heart-muscle cell transforming growth factor beta-1 receptor.

Binding of human-recombinant transforming growth factor-beta 1 (TGF-beta 1) to the neonatal rat heart-muscle cell (cardiomyocyte) was characterized as a potential element in the cardioprotective pharmacology of this growth factor. The cardiomyocytes were found to express a single class of specific, high-affinity TGF-beta 1 binding sites. Ligand binding to these sites was rapid, saturable, selective, and reversible, characteristics of a receptor-mediated process. Scatchard and iterative non-linear least-squares regression analyses demonstrated that the cardiomyocyte TGF-beta 1 receptor had a Kd < or = 40 pM, a Bmax of approximately 3.4 fmol/10(6) cells, and a density of approximately 2000 binding sites/cell. Binding was selective for TGF-beta 1 as compared with other TGF-beta isoforms (i.e. TGF-beta 2 and -beta 3) and nonrelated cytokines (e.g. acidic fibroblast growth factor). Affinity-binding experiments to probe the molecular nature of the specific binding revealed three types of cardiomyocyte TGF-beta 1 binding proteins, the most prominent of which corresponded to the high-molecular-mass proteoglycan observed in nonmuscle cell types. These data raise the possibility that the known pharmacological effects of TGF-beta 1 on heart muscle may be direct actions via specific receptor-mediated events.